Winnetnews.com – Chairman of the Indonesia Technical Advisory Group on Immunization (ITAGI) Prof. Sri Rezeki Hadinegoro explained the efficacy of vaccines AstraZeneca in the fight against the Corona virus that causes COVID-19. He revealed from clinical trials phase 2 and 3 in three countries, the results are very good.
Based on phase 2 and 3 clinical trials in the UK, Brazil and South Africa, it can be concluded that the AstraZeneca vaccine can protect against serious illness, treatment and death 100 percent. Especially after 22 days, after the first dose was given.
“The efficacy is also quite high, up to more than 80 percent if the interval for the second dose is at least 12 weeks or 3 months. So, don’t worry if AstraZeneca has a long interval, it has high efficacy,” explained Prof Sri Rezeki in an online workshop about AstraZeneca vaccine, Saturday (25/9/2021).
In addition, in phase 3 clinical trials in the United States also showed good results. The reason is, from these clinical trials, it shows that the AstraZeneca vaccine is able to fight severe or critical illnesses to reduce the risk of treatment, especially for the elderly over 65 years.
Vaksin AstraZeneca vs Variant of Concern (VoC)
Prof. Sri Rezeki said that the AstraZeneca vaccine has very good efficacy against Corona variants, especially those included in the variant of concern (VoC) group. This vaccine is also very good against the Delta variant that currently dominates in the world.
“We can assure our community that in real-world this vasin (AstraZeneca) is very good, especially for the Delta variant,” he said.
The following are the results of the AstraZeneca vaccine study against the Corona variant in the UK and Canada:
The UK study analyzed the effectiveness of the AstraZeneca vaccine against Alpha and Delta variants, in preventing hospitalization. Here are the results:
- For the Alpha variant, the first dose of AstraZeneca vaccine reached 76 percent efficacy. While in the second dose, the efficacy reached 86 percent.
- For the Delta variant, the first dose of AstraZeneca vaccine reached 71 percent efficacy. While in the second dose, the efficacy reached 92 percent.
“So for Indonesia, 81 percent of us are Delta. So, Alhamdulillah we can prevent 71 percent, especially if we have received the complete two-dose vaccine, it reaches 92 percent,” said Prof Sri Rezeki.
This Canadian study analyzed the effectiveness of the AstraZeneca vaccine against the emergence of symptoms caused by VoC, namely Alpha, Beta, Gamma, and Delta. This was seen more than 14 days after the first and second doses. Here are the results:
- For the Alpha variant, the first dose of AstraZeneca vaccine reached 64 percent efficacy. While in the second dose, the efficacy reaches 75 percent.
- For the Beta and Gamma variants, the first dose of AstraZeneca vaccine reached 48 percent efficacy. While in the second dose, the efficacy reaches 100 percent.
- For the Delta variant, the first dose of AstraZeneca vaccine reached 67 percent efficacy. While in the second dose, the efficacy reaches 100 percent.
“The real world, both in Europe and in Asia, shows that the effectiveness of AstraZeneca for VoC, especially Delta is quite encouraging. So, we don’t have to worry that even though there are many mutations, we can still control if all our people want to be immunized with the protocol. health strict,” he concluded.
This article has been published on health.detik.com with the title “AstraZeneca Vs Delta Cs Vaccine, How Effective? These are the results of studies in the real world“